Gastroduodenal Crohn's Disease Research Services

Gastroduodenal Crohn's disease is a type of inflammatory bowel disease that affects the stomach or upper part of the small intestine. It is a rare manifestation of Crohn's disease, affecting only about 5% of people with Crohn's disease. The most common symptoms are abdominal pain, nausea and vomiting. Chronic inflammation also causes scar tissue to form, narrowing the stomach outlet. In some cases, chronic anemia may develop due to gastrointestinal blood loss. Diagnosis is usually made by a comprehensive clinical evaluation, including endoscopy with biopsy. Furthermore, there is currently no treatment that can provide a permanent cure for this condition. As a result, continued research is necessary to better understand the underlying mechanisms and develop more effective therapeutic options.

Fig. 1. Stricturing disease of the duodenum. (Lightner, 2018)

Customized Studies for Gastroduodenal Crohn's Disease

Preclinical research and therapeutic development are essential to the cure of gastroduodenal Crohn’s disease, and Ace Therapeutics does exactly that to make sure you find the next treatment breakthrough for gastroduodenal Crohn’s disease.

Diagnostic Development Services for Gastroduodenal Crohn's Disease

Ace Therapeutics brings the extensive scientific experience and technology to work on making a good diagnostic for gastroduodenal Crohn’s disease for biotechnology and pharmaceutical companies. With the most sophisticated lab equipment and interfacing multi-omics workflows, we’re making biomarker expression and detection easy for you in gastroduodenal Crohn’s disease.

• Biomarker development and detection. By analyzing blood samples, we help our clients identify biomarkers, such as cytokines, proteins, and metabolites, associated with gastroduodenal Crohn's disease. Our high-throughput assay platform enables rapid and efficient biomarker detection.
• Imaging technology development. Our experts help clients develop new imaging technologies, such as fluoroscopic double-contrast radiography, computed tomography enterography (CTE), or magnetic resonance enterography (MRE), to provide more sensitive and specific information for gastroduodenal Crohn's disease diagnostics.
• Preclinical validation. We use animal models of Crohn's disease to validate the diagnostic performance of biomarkers and imaging techniques.
• Genetic studies. A genome-wide scan in animal models of Crohn's disease to define new predisposing genes associated with Crohn's disease with gastroduodenal involvement.

Therapy Development Services for Gastroduodenal Crohn's Disease

We are committed to assisting our clients in the development of a wide range of drugs (e.g. corticosteroids, proton pump inhibitors, biologic therapy with anti-TNF therapy) and the evaluation of the efficacy of these drugs in animal models of Crohn's disease.

• Analyzing the role of TNF signaling pathway in gastroduodenal Crohn's disease.
• Screening and optimizing high-affinity anti-TNF monoclonal antibodies using methods such as hybridoma technology or phage display.
• In vitro and in vivo pharmacological evaluation of antibody to assess activity, selectivity and safety.
• Engineering modifications to improve the pharmacokinetic properties of antibody candidates, such as half-life, immunogenicity.
• Conducting detailed toxicology, pharmacodynamics and pharmacokinetic studies.

Ace Therapeutics is dedicated to advancing research in gastroduodenal Crohn's disease for pharmaceutical companies. With our significant expertise and reliable animal models, we offer comprehensive, one-stop services for the preclinical development of your innovative gastroduodenal Crohn's disease therapies. If you are interested in our services, please do not hesitate to contact us.